Elevatedheartrateisamajorriskfactorforcardiovasculardiseases.Theinhibitoroffunnycurrent(I(f)),ahyperpolarization-activatedcyclicnucleotide-gatedchannelcurrent,ivabradineisanewagentselectivelyreducingheartratedevoidofothercardiovasculareffects,whichhascomeintothemarketinEuropeformorethan3years.Ithasbeenapprovedthatpureheartratereductionbyivabradinecanimprovemyocardialischemia,endothelialfunctionandmyocardialcontractilefunction.Long-termadministrationwillnotincreaseall-causemortality.Itstherapeuticvalueinstablecoronaryarterydiseasehasbeenverifiedinclinicalpractice,whileinotherfieldsofcardiovasculardiseasesstillneedsmoreevidence-basedmedicalresearch.Thisarticleisareviewaboutitsrecentresearchadvancesinexperimentalandclinicalstudies.
